Conatus Pharmaceuticals Inc
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2022 | $5 M | No. 4 | $2 to $10 million | options | SEC | |
| May 2013 | $1 M | No. 3 | Under $2 million | debt, options | SEC | |
| Feb 2011 | $25 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2010 | $5 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Conatus Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Jul 2022).
SEC Form D · Jul 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2022
That is all the official record says: Conatus Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Aberdare GP III, L.L.C. | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Aberdare Partners III LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Aberdare Ventures III LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Advent Venture Partners LLP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Cooperative Gilde Healthcare II U.a. | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM Asset Management Investors BV4 LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM Asset Management Investors BV5 LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM BioVentures IV GmbH & Co. Beteiligungs KG | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM BioVentures IV GP LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM BioVentures IV LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM BioVentures IV QP LP | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM Bioventures V GP LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM Bioventures V LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| MPM Bioventures V, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 21 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gail K. Naughton | Executive officer | Jul 2022 |
| Joyce J. Reyes | Executive officer | Jul 2022 |
| Martin K. Latterich | Executive officer | Jul 2022 |
| Steven J. Mento | Executive officer | Jul 2022 |
| Susan A. Knudson | Executive officer | Jul 2022 |
| Alfred P. Spada, Ph.D. | Executive officer | Jun 2013 |
| Charles J. Cashion | Executive officer | Jun 2013 |
| Gary C. Burgess | Executive officer | Jun 2013 |
| Steven J. Mento, Ph.D. | Executive officer | Jun 2013 |
| Alfred P. Spada | Executive officer | Feb 2011 |
| Jennifer Giottonini Cayer | Executive officer | Feb 2011 |
| Brian L. Satz | Director | Jul 2022 |
| Daniel L. Kisner | Director | Jul 2022 |
| David H. Crean | Director | Jul 2022 |
| Jonathan H. Jackson | Director | Jul 2022 |
| Rochelle L. Fuhrmann | Director | Jul 2022 |
| Steven J. Mento | Director | Jul 2022 |
| Susan L. Windham-Bannister | Director | Jul 2022 |
| David F. Hale | Director | Jun 2013 |
| Harold H. Van Wart, M.D. | Director | Jun 2013 |
| James H. Scopa | Director | Jun 2013 |
| Louis H. Lacasse | Director | Jun 2013 |
| Marc H. Perret | Director | Jun 2013 |
| Paul H. Klingenstein | Director | Jun 2013 |
| Shahzad H. Malik, M.D. | Director | Jun 2013 |
| Steven J. Mento, Ph.D. | Director | Jun 2013 |
| William F. Gerber, M.D. | Director | Jun 2013 |
| Harold F. Van Wart | Director | Feb 2011 |
| Louis F. Lacasse | Director | Feb 2011 |
| Marc F. Peret | Director | Feb 2011 |
| Paul F. Klingenstein | Director | Feb 2011 |
| Shahzad F. Malik | Director | Feb 2011 |
| William J. Gerber | Director | Feb 2011 |